Calliditas Therapeutics

NASDAQ CALT

Data sourced from

and

Download Data

Calliditas Therapeutics Non-Current Liabilities (Other) 3 year CAGR for the year ending December 31, 2023: 336.34%

Calliditas Therapeutics Non-Current Liabilities (Other) 3 year CAGR is 336.34% for the year ending December 31, 2023. Non-Current Liabilities (Other) are non-current liabilities that are not classified under long-term debt. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Calliditas Therapeutics Non-Current Liabilities (Other) for the year ending December 31, 2022 was SEK 80.23 M, a 47.49% change year over year.
Calliditas Therapeutics Non-Current Liabilities (Other) for the year ending December 31, 2021 was SEK 54.40 M, a 6,095.67% change year over year.
Calliditas Therapeutics Non-Current Liabilities (Other) for the year ending December 31, 2020 was SEK 878.00 K.

NASDAQ: CALT

Calliditas Therapeutics

CEO	Ms. Renee Aguiar-Lucander
IPO Date	June 5, 2020
Location	Sweden
Headquarters	Kungsbron 1, D5, Stockholm, Sweden, 111 22
Employees	217
Sector	Healthcare
Industry	Biotechnology

Description

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Key trends